Fake Carbs Practice With AID System - MiniMed 780G in Children and Adolescents With T1D.

Aim of the Study To compare glycemic control outcomes in individuals with T1D using the MiniMed™ 780G system during periods when 'fake carbohydrates' are used versus periods when this strategy is not employed.

Definition: Fake Carbohydrates As a Fake Carbs practice is defined the practice when the user enters fake quantity of carbohydrates in order to trigger the system to suggest and deliver a bolus insulin with the aim to correct hyperglycemia.

Study Design and Participants This is a prospective, open-label, randomized, crossover trial conducted at the Diabetes Center of the General Hospital "P. \& A. Kyriakou" in Athens, Greece.

Sample Size

* Total Participants: 40 children and adolescents * Age Range: 7-18 years Inclusion Criteria * Diagnosis of T1D * Using the MiniMed™ 780G system for ≥6 months * Habitual use of fake carbohydrates in daily management Exclusion Criteria * Severe diabetes-related complications * Recent episodes of diabetic ketoacidosis (DKA) or severe hypoglycemia Randomization and Group Allocation

Participants will be randomized into two groups based on their prior use of fake carbohydrates:

Group 1 (FC1): Continue using fake carbohydrates for 2 weeks, followed by discontinuation for 2 weeks.

Group 2 (FC2): Discontinue use of fake carbohydrates for 2 weeks, followed by resumption for 2 weeks.

Each intervention phase will be preceded by a 2-week run-in period to allow algorithm adaptation. A 2-week washout period between crossover phases will follow the same adaptation rationale.

Baseline and Ongoing Assessments

* Clinical and Demographic Data * Age, sex, T1D duration, weight, height * HbA1c measured via HPLC (Menarini) on a single analyzer All data retrieved from hospital electronic medical records

MiniMed™ 780G System Data

Review of pump settings during run-in phase

Settings optimized using:

* Target glucose: 100 mg/dL * Active Insulin Time: 2 hours

Fake Carbohydrates Logbook

Participants will maintain a log recording:

* Time, amount, and context of fake carbohydrate entries * Real meals and blood glucose levels * Any episodes of hypoglycemia following fake CHO entries

Outcome Measures

* Primary Outcome Time in Range (TIR 70-180 mg/dL) over each 2-week intervention phase * Secondary Outcomes Time below range (\<70 mg/dL) and time above range (\>180 mg/dL) Total daily insulin dose Frequency and severity of hypoglycemia System usage data (auto-mode %, correction boluses) Number and frequency of meal and fake CHO entries Adverse events (e.g., severe hypoglycemia, DKA)

Data Collection Tools CareLink™ Software: Used for glycemic data at baseline, week 2, and week 4 Participant logbooks for qualitative assessment of FC practices

Data Analysis Within-subject comparisons will be conducted due to crossover design Descriptive statistics for demographic and baseline characteristics Paired t-tests or Wilcoxon signed-rank tests for primary and secondary outcomes Repeated-measures ANOVA for longitudinal outcomes

Expected Impact This study will provide the first structured evaluation of the widely used but clinically unverified practice of entering 'fake carbohydrates' in AHCL systems. It will inform clinicians on whether this strategy improves or undermines glycemic control and support evidence-based recommendations for pump users and healthcare providers.

• Changes between groups in GMI [Time frame: 2 weeks]
• Changes in Time Above Range [Time frame: 2 weeks]
• Change in mean sensor glucose [Time frame: 2 weeks]
• Change in Standard Deviation of glucose [Time frame: 2 weeks]
• Changes in Coefficient of Variation for glucose [Time frame: 2 weeks]
• Changes in number of announced carbs [Time frame: 2 weeks]
• Changes in total daily insulin dose [Time frame: 2 weeks]
• Changes in insulin Auto-basal rate [Time frame: 2 weeks]
• Changes in insulin Auto-correction [Time frame: 2 weeks]
• Changes in insulin Manual bolus [Time frame: 2 weeks]
• Changes in number of severe hypoglycemia episodes [Time frame: 2 weeks]
• Changes in the number of diabetic ketoacidosis (DKA) events [Time frame: 2 weeks]